

This is a preview of "ISO 22442-3:2007". [Click here to purchase the full version from the ANSI store.](#)

First edition
2007-12-15

Medical devices utilizing animal tissues and their derivatives —

Part 3:

Validation of the elimination and/or inactivation of viruses and transmissible spongiform encephalopathy (TSE) agents

Dispositifs médicaux utilisant des tissus animaux et leurs dérivés —

*Partie 3: Validation de l'élimination et/ou de l'inactivation des virus et
autres agents responsables d'encéphalopathie spongiforme
transmissible (EST)*



Reference number
ISO 22442-3:2007(E)

© ISO 2007

This is a preview of "ISO 22442-3:2007". [Click here to purchase the full version from the ANSI store.](#)

PDF disclaimer

This PDF file may contain embedded typefaces. In accordance with Adobe's licensing policy, this file may be printed or viewed but shall not be edited unless the typefaces which are embedded are licensed to and installed on the computer performing the editing. In downloading this file, parties accept therein the responsibility of not infringing Adobe's licensing policy. The ISO Central Secretariat accepts no liability in this area.

Adobe is a trademark of Adobe Systems Incorporated.

Details of the software products used to create this PDF file can be found in the General Info relative to the file; the PDF-creation parameters were optimized for printing. Every care has been taken to ensure that the file is suitable for use by ISO member bodies. In the unlikely event that a problem relating to it is found, please inform the Central Secretariat at the address given below.



COPYRIGHT PROTECTED DOCUMENT

© ISO 2007

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying and microfilm, without permission in writing from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
Case postale 56 • CH-1211 Geneva 20
Tel. + 41 22 749 01 11
Fax + 41 22 749 09 47
E-mail copyright@iso.org
Web www.iso.org

Published in Switzerland

This is a preview of "ISO 22442-3:2007". [Click here to purchase the full version from the ANSI store.](#)

Contents

Page

Foreword.....	iv
Introduction	v
1 Scope	1
2 Normative references	1
3 Terms and definitions.....	2
4 General requirements.....	3
4.1 Risk management	3
4.2 Sourcing and manufacturing process	3
4.3 General requirements related to validation	3
5 Literature review	4
5.1 Conduct of the literature review	4
5.2 Application of literature review output	4
5.3 Viruses	4
5.4 TSE agents	4
6 Elimination and/or inactivation study of viruses and TSE agents	5
6.1 General.....	5
6.2 Protocol	5
6.3 Conduct of the study	6
6.4 Interpretation of data	6
7 Final report	6
8 Review of final report	6
9 Routine monitoring and control of critical process parameters	6
Annex A (normative) Requirements related to literature review	7
Annex B (informative) Guidance on the elimination and/or inactivation study for viruses	11
Annex C (informative) Guidance on the elimination and/or inactivation study for TSE agents	16
Annex D (informative) Guidance on scaling down	17
Annex E (informative) Statistical evaluation of virus titres and reduction factors and assessment of their validity	18
Annex F (informative) Calculation of reduction factors	19
Annex G (informative) Probability of detection of agents at low concentrations.....	20
Bibliography	21

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

International Standards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2.

The main task of technical committees is to prepare International Standards. Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75 % of the member bodies casting a vote.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights.

ISO 22442-3 was prepared by Technical Committee ISO/TC 194, *Biological evaluation of medical devices*, Subcommittee SC 1, *Tissue product safety*.

ISO 22442 consists of the following parts, under the general title *Medical devices utilizing animal tissues and their derivatives*:

- *Part 1: Application of risk management*
- *Part 2: Controls on sourcing, collection and handling*
- *Part 3: Validation of the elimination and/or inactivation of viruses and transmissible spongiform encephalopathy (TSE) agents*

This is a preview of "ISO 22442-3:2007". [Click here to purchase the full version from the ANSI store.](#)

Introduction

Certain medical devices utilize materials of animal origin.

Animal tissues and their derivatives are used in the design and manufacture of medical devices to provide performance characteristics that were chosen for advantages over non-animal based materials. The range and quantities of materials of animal origin in medical devices vary. These materials can comprise a major part of the device (e.g. bovine/porcine heart valves, bone substitutes for use in dental or orthopaedic applications, haemostatic devices), can be a product coating or impregnation (e.g. collagen, gelatine, heparin), or can be used in the device manufacturing process (e.g. tallow derivatives such as oleates and stearates, foetal calf serum, enzymes, culture media).

It is important to be aware that the exposure to a properly validated and accurately controlled method of viral and TSE inactivation/elimination is not the only factor associated with demonstrating product safety. Attention has also to be given to a number of factors including sourcing, collecting, handling, storage, processing, testing of tissues and/or cells of animal origin, and to the control of the environment in which the product is manufactured, assembled and packaged. The manufacturer should consider the fact that each manufacturing phase can contribute to contamination as well as elimination and/or inactivation of viruses and TSE agents.

For the safety of medical devices there are two complementary approaches (see ISO 22442-1) that can be adopted to control the potential contamination of tissues. These typically are:

- a) selecting source material for minimal contamination with viruses and/or TSE agents (see ISO 22442-1 and ISO 22442-2);
- b) providing valid scientific evidence to demonstrate the ability of the production processes to eliminate or inactivate viruses and/or TSE agents (this part of ISO 22442).

Requirements for a quality system for medical devices for regulatory use are specified in ISO 13485. The standards for quality management systems recognize that, for certain processes used in manufacturing, the effectiveness of that process cannot be fully verified by subsequent inspection and testing of the product. The elimination and/or inactivation of viruses and TSE agents is an example of a special process because process efficacy cannot be verified by inspection and testing of the product. For this reason, the following need to be considered in particular:

- definition of the process(es) and materials to be used;
- adequate inactivation validation before routine use;
- performance monitoring of the process during manufacture;
- appropriate equipment maintenance;
- staff training, etc.

Historically there have been many instances of unknown or unsuspected viral contamination during manufacture. For this reason, evaluation of the manufacturing process can provide a measure of confidence that a wide number of viruses, including unknown pathogenic viruses are eliminated. Similar principles may apply to TSE agents.

NOTE To show compliance with this part of ISO 22442, its specified requirements should be fulfilled. The guidance given in the Notes and informative annexes is not normative and is not provided as a checklist for auditors.